Pandelakis A. Koni

Pandelakis A. Koni

Auto-generated profile, based on publicly available information

Pandelakis A. Koni

§Parker Institute for Cancer Immunotherapy, San Francisco, CA 94129; and

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2013 in Nature
Verified
Journal Article
Open access
PDF file
MHMatthew R. Hepworth
Matthew R. Hepworth
LMLaurel A. Monticelli
Laurel A. Monticelli
TFThomas C. Fung
Thomas C. Fung
CZCarly G. K. Ziegler
Carly G. K. Ziegler
SGStephanie Grunberg
Stephanie Grunberg
GSGregory F. Sonnenberg
Gregory F. Sonnenberg
Group 3 innate lymphoid cells are shown to process and present antigen and to control CD4+ T-cell responses to intestinal commensal bacteria through an MHC-class-II-dependent mechanism. The recently characterized innate lymphoid cells (ILCs) can be classified functionally into three groups. Group 1 ILCs produce interferon-γ, group 2 cells express interleukin (IL)-5, IL-13 and amphiregulin, and group 3 ILCs produce IL-17A and IL-22. The function of ILCs in the presence of adaptive immunity and their potential to influence adaptive immune cell responses are largely unknown. A study in mice now shows that group 3 ILCs process and present antigen and control CD4+ T-cell responses to intestinal commensal bacteria through an MHC-class-II-dependent mechanism. This finding may be relevant to the pathogenesis of chronic human diseases associated with inflammatory host immune responses to commensal bacteria. Innate lymphoid cells (ILCs) are a recently characterized family of immune cells that have critical roles in cytokine-mediated regulation of intestinal epithelial cell barrier integrity1,2,3,4,5,6,7,8,9,10. Alterations in ILC responses are associated with multiple chronic human diseases, including inflammatory bowel disease, implicating a role for ILCs in disease pathogenesis3,8,11,12,13. Owing to an inability to target ILCs selectively, experimental studies assessing ILC function have predominantly used mice lacking adaptive immune cells1,2,3,4,5,6,7,8,9,10. However, in lymphocyte-sufficient hosts ILCs are vastly outnumbered by CD4+ T cells, which express similar profiles of effector cytokines. Therefore, the function of ILCs in the presence of adaptive immunity and their potential to influence adaptive immune cell responses remain unknown. To test this, we used genetic or antibody-mediated depletion strategies to target murine ILCs in the presence of an adaptive immune system. We show that loss of retinoic-acid-receptor-related orphan receptor-γt-positive (RORγt+) ILCs was associated with dysregulated adaptive immune cell responses against commensal bacteria and low-grade systemic inflammation. Remarkably, ILC-mediated regulation of adaptive immune cells occurred independently of interleukin (IL)-17A, IL-22 or IL-23. Genome-wide transcriptional profiling and functional analyses revealed that RORγt+ ILCs express major histocompatibility complex class II (MHCII) and can process and present antigen. However, rather than inducing T-cell proliferation, ILCs acted to limit commensal bacteria-specific CD4+ T-cell responses. Consistent with this, selective deletion of MHCII in murine RORγt+ ILCs resulted in dysregulated commensal bacteria-dependent CD4+ T-cell responses that promoted spontaneous intestinal inflammation. These data identify that ILCs maintain intestinal homeostasis through MHCII-dependent interactions with CD4+ T cells that limit pathological adaptive immune cell responses to commensal bacteria.

1 April 1997 in Immunity
Verified
Journal Article
Open access
PKPandelakis A Koni
Pandelakis A Koni
RSRosalba Sacca
Rosalba Sacca
PLPornsri Lawton
Pornsri Lawton
JBJeffrey L Browning
Jeffrey L Browning
NRNancy H Ruddle
Nancy H Ruddle
RFRichard A Flavell
Richard A Flavell
Lymphotoxin alpha (LT alpha)-deficient mice revealed critical roles for LT alpha in lymphoid organogenesis, but it is not clear whether LT alpha functions through an LT alpha homotrimer (LT alpha3) or LT alpha/beta heterotrimers. We generated LTbeta-deficient mice and found them to lack Peyer's patches, peripheral lymph nodes, splenic germinal centers, and follicular dendritic cells. Unlike LT alpha-deficient mice, LT beta-deficient mice had cervical and mesenteric lymph nodes. Furthermore, the mesenteric lymph nodes had germinal center-like regions, although these structures appeared to lack follicular dendritic cells. The absence of cervical and mesenteric lymph nodes in LT alpha-deficient mice, and yet their presence in LT beta-deficient mice and in mice deficient in tumor necrosis factor receptor types I and II, suggest that LT alpha3 may signal via an as yet unidentified receptor.

19 March 2001 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
PKPandelakis A. Koni
Pandelakis A. Koni
SJSunil K. Joshi
Sunil K. Joshi
UTUlla-Angela Temann
Ulla-Angela Temann
DODian Olson
Dian Olson
LBLinda Burkly
Linda Burkly
RFRichard A. Flavell
Richard A. Flavell
We generated vascular cell adhesion molecule (VCAM)-1 “knock-in” mice and Cre recombinase transgenic mice to delete the VCAM-1 gene (vcam-1) in whole mice, thereby overcoming the embryonic lethality seen with conventional vcam-1–deficient mice. vcam-1 knock-in mice expressed normal levels of VCAM-1 but showed loss of VCAM-1 on endothelial and hematopoietic cells when interbred with a “TIE2Cre” transgene. Analysis of peripheral blood from conditional vcam-1–deficient mice revealed mild leukocytosis, including elevated immature B cell numbers. Conversely, the bone marrow (BM) had reduced immature B cell numbers, but normal numbers of pro-B cells. vcam-1–deficient mice also had reduced mature IgD+ B and T cells in BM and a greatly reduced capacity to support short-term migration of transferred B cells, CD4+ T cells, CD8+ T cells, and preactivated CD4+ T cells to the BM. Thus, we report an until now unappreciated dominant role for VCAM-1 in lymphocyte homing to BM.

15 August 2009 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
BBBabak Baban
Babak Baban
PCPhillip R. Chandler
Phillip R. Chandler
MSMadhav D. Sharma
Madhav D. Sharma
JPJeanene Pihkala
Jeanene Pihkala
PKPandelakis A Koni
Pandelakis A Koni
AMAndrew L. Mellor
Andrew L. Mellor
TLR ligands are effective vaccine adjuvants because they stimulate robust proinflammatory and immune effector responses and they abrogate suppression mediated by regulatory T cells (Tregs). Paradoxically, systemic administration of high doses of CpGs that bind to TLR9 ligands stimulated Tregs in mouse spleen to acquire potent suppressor activity dependent on interactions between programmed death-1 and its ligands. This response to CpG treatment manifested 8–12 h and was mediated by a rare population of plasmacytoid dendritic cells (CD19+ pDC) induced to express the immunosuppressive enzyme IDO after TLR9 ligation. When IDO was blocked, CpG treatment did not activate Tregs, but instead stimulated pDCs to uniformly express the proinflammatory cytokine IL-6, which in turn reprogrammed Foxp3-lineage Tregs to express IL-17. Thus, CpG-induced IDO activity in pDCs acted as a pivotal molecular switch that induced Tregs to acquire a stable suppressor phenotype, while simultaneously blocking CpG-induced IL-6 expression required to reprogram Tregs to become Th17-like effector T cells. These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings.

15 August 2003 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
AMAndrew L. Mellor
Andrew L. Mellor
BBBabak Baban
Babak Baban
PCPhillip Chandler
Phillip Chandler
BMBrendan Marshall
Brendan Marshall
KJKanchan Jhaver
Kanchan Jhaver
DMDavid H. Munn
David H. Munn
In mice, immunoregulatory APCs express the dendritic cell (DC) marker CD11c, and one or more distinctive markers (CD8α, B220, DX5). In this study, we show that expression of the tryptophan-degrading enzyme indoleamine 2,3 dioxygenase (IDO) is selectively induced in specific splenic DC subsets when mice were exposed to the synthetic immunomodulatory reagent CTLA4-Ig. CTLA4-Ig did not induce IDO expression in macrophages or lymphoid cells. Induction of IDO completely blocked clonal expansion of T cells from TCR transgenic mice following adoptive transfer, whereas CTLA4-Ig treatment did not block T cell clonal expansion in IDO-deficient recipients. Thus, IDO expression is an inducible feature of specific subsets of DCs, and provides a potential mechanistic explanation for their T cell regulatory properties.

15 July 2004 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DMDavid H. Munn
David H. Munn
MSMadhav D. Sharma
Madhav D. Sharma
DHDeyan Hou
Deyan Hou
BBBabak Baban
Babak Baban
JLJeffrey R. Lee
Jeffrey R. Lee
AMAndrew L. Mellor
Andrew L. Mellor
One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively expressed immunosuppressive levels of the enzyme indoleamine 2,3-dioxygenase (IDO). Despite comprising only 0.5% of LN cells, these pDCs in vitro potently suppressed T cell responses to antigens presented by the pDCs themselves and also, in a dominant fashion, suppressed T cell responses to third-party antigens presented by nonsuppressive APCs. Adoptive transfer of DCs from TDLNs into naive hosts created profound local T cell anergy, specifically toward antigens expressed by the transferred DCs. Anergy was prevented by targeted disruption of the IDO gene in the DCs or by administration of the IDO inhibitor drug 1-methyl-D-tryptophan to recipient mice. Within the population of pDCs, the majority of the functional IDO-mediated suppressor activity segregated with a novel subset of pDCs coexpressing the B-lineage marker CD19. We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses.